AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
Key Highlights
- ➤Sanofi (SNY) agreed to pay Regeneron $1 billion upfront for four antibodies
- ➤Eli Lilly invested $40 million in Absci (ABSI) through a $100 million offering
- ➤Absci (ABSI) reported positive interim Phase 1 data for ABS-201
- ➤Generate (GENB) advanced a Novartis-designed biologic into its preclinical pipeline
- ➤MindWalk (HYFT) appointed three senior leaders as its pipeline approaches preclinical efficacy studies
Expert Statements
Jennifer Bath, President and Chief Executive Officer of MindWalk Holdings Corp.
“Preclinical efficacy is where a program’s value starts to be defined, and it is the stage our pipeline is now approaching. Joanne has taken programs from concept through candidate nomination and knows what an efficacy package has to show. Zachary gives us internal structural confirmation that a construct presents what we designed before it enters animal studies. Shuji brings twenty years of antibody development and a working knowledge of our platform and partners to the question of which assets deserve continued investment. Where our programs run on ReefIQ™ and LensAI™, what they generate feeds back into the platform our partners use, so the pipeline and the platform strengthen each other.”
Mike Nally, Chief Executive Officer of Generate Biomedicines, Inc.
“With GB-0895, our global Phase 3 SOLAIRIA studies in severe asthma continue to advance”
Sean McClain, Founder and CEO of Absci Corporation
“This is just the beginning for our prolactin receptor franchise within our overall proprietary pipeline”
Belén Garijo, Chief Executive Officer of Sanofi
“This is a deliberate first step in igniting Sanofi’s innovation engine”
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Boston. Companies mentioned in today’s commentary include: MindWalk Holdings Corp. (NASDAQ: HYFT), Generate Biomedicines, Inc. (NASDAQ: GENB), Moderna, Inc. (NASDAQ: MRNA), Absci Corporation (NASDAQ: ABSI), Sanofi (NASDAQ: SNY).
Get started
Create a free account to read the full story.